To target or not to target APRIL in systemic lupus erythematosus: that is the question!

Morel, J.; Hahne, M.

Arthritis Res Ther

2013-02-25 / vol 15 / pages 107


ABSTRACT: Among the cytokines that regulate B-cell homeostasis are the TNF-like ligands B-lymphocyte stimulator (BLyS; also B-cell activation factor) and a proliferation-inducing ligand (APRIL). BLyS and APRIL share two receptors; that is, B-cell maturation antigen and transmembrane activator and CAML interactor. Therapeutic approaches using biologics are limited for treatment of lupus patients. One previously approved drug is belimumab, which antagonizes the B-cell stimulator BLyS. Atacicept, another biologic inhibiting BLyS and APRIL, was terminated for serious adverse events – raising the question of whether APRIL should be neutralized in autoimmune diseases.

Lire sur PubMed

ar4160 [pii] 10.1186/ar4160

1478-6362 (Electronic) 1478-6354 (Linking)

Toutes les publications